A special kind of genetic test that helps determine the best antidepressant for patients with moderate-to-severe depression could generate substantive health system savings and greatly improve patient outcomes, according to new research. The study shows that in B.C. alone, implementing pharmacogenomic testing could save the provincial public health system an estimated $956 million over 20 years.